Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: CPAMarty who wrote (53)	10/29/1997 9:14:00 AM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 2515

Well, I doubled my position at 6 3/8. I just hope I don't jinx this baby. IMCL has enormous potential; I can see that by the price elasticity of the stock and the substantial insider purchases. Jackson

To: CPAMarty who wrote (53)	11/6/1997 11:42:00 PM
From: CPAMarty	Read Replies (1) \| Respond to of 2515

NEW YORK--(BW HealthWire)--Nov. 5, 1997--ImClone Systems Incorporated (Nasdaq:IMCL) announced today that the Company has acquired exclusive rights to a recently discovered protein which may play an important role in the early growth of cancers. This protein, referred to as VE-cadherin-2, is believed to enable the formation of a capillary blood vessel network in solid tumors, an essential step in the uncontrolled growth of malignancies. ImClone Systems is developing antagonists to VE-cadherin-2 to inhibit tumor vascularization. In connection with its acquisition of exclusive relevant patent applications, the Company initiated a collaboration with Mario Negri Institute (Milan, Italy) to conduct pharmacological research in the laboratory of Elisabetta Dejana, Ph.D., who is investigating the role of VE-cadherin-2 in angiogenesis. "At ImClone, VE-cadherins represent new targets for anti-cancer therapeutics that complement the Company's ongoing anti-angiogenesis program," commented Peter Bohlen, Ph.D., Vice President of Research at ImClone Systems. "Our near-term goal is to apply proprietary molecular design and high-throughput screening assays that can identify small-molecule and antibody-based inhibitors of VE-cadherins." ImClone Systems' lead anti-angiogenesis compound is a monoclonal antibody that inhibits the tyrosine kinase receptor known as KDR/FLK-1, located on tumor-associated capillary blood vessels. The KDR/FLK-1 receptor, when stimulated by tumor-derived vascular growth factor, VEGF, mediates the tumor-associated formation of new blood vessels. ImClone scientists are conducting preclinical research to determine potential clinical utility of the Company's monoclonal-antibody antagonist of KDR/FLK-1 and to obtain regulatory approval for clinical studies. ImClone Systems has two oncology products in late-stage clinical development and is advancing earlier drug candidates to the clinical stage. The Company is currently evaluating C225, an epidermal growth factor receptor (EGFr) antagonist, in head and neck cancer patients in three Phase Ib/IIa dose-escalation trials in combination with other anti-cancer therapies. ImClone expects to initiate Phase II/III studies to evaluate the potential of C225 in various tumor types. In addition, ImClone intends to initiate a Phase III multinational trial in small cell lung cancer patients with the Company's anti-cancer vaccine, BEC2, in the fourth quarter of this year. ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical company developing novel therapeutic products including interventional therapeutics, cancer vaccines and blood cell growth factors for the treatment of cancer and cancer-related disorders. -0- Except for the historical information contained herein, the matters discussed in this news release may include forward-looking statements. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Companies' businesses, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance of and continuing demand for the Companies' products, the impact of competitive products and pricing, and the Companies' ability to obtain additional financing to support their operations. The Companies undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. CONTACT: ImClone Systems Incorporated, New York Andrea F. Rabney Director of Corporate Development and Investor Relations 212/645-1405 or Burns McClellan, Inc., New York Reagan Codner, Investors Justin Jackson, Media 212/213-0006 KEYWORD: NEW YORK BW1081 NOV 05,1997